Sylmark Holdings Limited

Apollo Endosurgery, Inc.

Apollo Endosurgery Us, Inc.

Covidien Ag

Sherwood Services Ag

Allergan, Inc.

Mitchell H. Babkes

Y. Denis Yerlikaya

Mitchell H Babkes

Zachary Dominguez

Justin J Schwab

Christopher S Mudd

Tiago Bertolote

Dean G Tornabene

Clarence Walker

Henry J Howell

James M Harr

Richard Jin Law

Joseph S Raven

Brett Ryan Johnson

Kevin C Meier

Glenn Fournie

Mark A Davis

Michael J Prichard

Shaohui Qiu

Jason Metzner

Lee F Powers

Martha E Llewellyn

Sean Snow

Michael J Kerwin

Craig Olroyd

Jason Hoover

Jonathan Daugusta

Brian Fitzburgh

Mark Ellis

Lee C Burnes

Walker Clarence

Y Denis Yerlikaya

Zachary P Dominguez

Glenn G Fournie

An intragastric implant for obesity treatment is disclosed. The device delays digestion by providing a duodenal sleeve, and may also slows gastric emptying by limiting flow through the pyloric sphincter. The implant includes an elongated axially-compressible duodenal sleeve having a non-tissue-piercing anchor on a proximal end sized to lodge within the duodenal bulb. The anchor may have oppositely-directed anchoring flanges to resists migration in both directions. The sleeve may also have barbed ribs to resist proximal movement back up into the stomach. A method of implant includes collapsing/compressing the device and transorally advancing it through the esophagus to be deployed within the duodenum. A dissolvable jacket may constrain the implant for delivery and naturally dissolve upon implant. Removal of the implant may occur in the reverse.

Anchored non-piercing duodenal sleeve and delivery systems

A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may provide slowed entry into the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Some devices combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse. The implants are formed of materials that permit the implant to be compressed into a substantially linear transoral delivery configuration and that will resist degradation over a period of at least six months within the stomach.

Upper stomach gastric implants

Transoral implantable devices includes an inflatable body made of a material that permits it to be compressed into a substantially linear transoral delivery configuration and that when implanted in the stomach is adapted to reduce obesity or weight by stimulating the stomach walls of the patient. The body has a plurality of popout features on its surface that reside generally flush with the inflatable body in relaxed, refracted states, and which respond to an increase in pressure within the inflatable body by projecting outward from the body in a stressed, deployed state. The popout features may convert between their retracted and deployed states by movement of rolling diaphragms formed in the inflatable body.

Reactive intragastric implant devices

A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may take up volume within the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Also, certain devices slow gastric emptying by blocking or otherwise impeding flow through the pyloric sphincter. A number of devices combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse.

Space-filling intragastric implants with fluid flow

A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may take up volume within the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, or the greater and lesser curvatures in the middle of the stomach, to stimulate satiety-inducing nerves. Some devices may combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse.

Non-inflatable gastric implants and systems

A transorally implanted intragastric balloon or treating obesity and for weight control including a variable size balloon with one or interconnected regions acting to exert a pressure on the stomach, to provide a stomach volume occupying effect, and/or to anchor the balloon within the stomach.

Intragastric balloon for treating obesity

Transoral obesity treatment devices and related methods for operation thereof are described which occupy space within a stomach and/or stimulate the stomach wall. The transoral obesity treatment devices and related methods are intended to assist a patient in maintaining a healthy body weight. Features of the devices include insertion transorally and without invasive surgery, without associated patient risks of invasive surgery, and without substantial patient discomfort. The life span of these devices may be material-dependent upon long-term survivability within an acidic stomach, but is intended to last one year or longer. The devices have the capacity to vary in size and are desirably self-actuating in that they change shape and/or volume using internal motors or actuators. The changing character of the devices helps prevent the person's stomach from compensating for the implant, such as sometimes happens with static intragastric devices.

Intragastric implants with collapsible frames

Intragastric fluid transfer devices and related methods for operation thereof are disclosed. The intragastric fluid transfer devices and related methods are intended to assist a patient in maintaining a healthy body weight by stimulating the inner stomach walls and/or the inner duodenum walls. Features of the intragastric fluid transfer device include insertion of the devices transorally and without invasive surgery, without associated patient risks of invasive surgery, and without substantial patient discomfort. The life span of these intragastric fluid transfer devices may be material-dependent upon long-term survivability within an acidic stomach, but is intended to last one year or longer.

Intragastric implants with duodenal anchors

A mechanism for removing a fluid-filled object such as an intragastric balloon from a patient. The apparatus includes a delivery tube having a lumen and a retrieval tool able to slide within the lumen that can both puncture and grasp the intragastric balloon. The retrieval tool may have sharpened graspers with either a sharp tip and/or knife-like edges. Alternatively, the delivery tube itself may have sharpened cutting blades that deploy outward to puncture the intragastric balloon. One embodiment utilizes a suction cup tip on the delivery sheath and a sharpened puncture rod that extends past the distal tip of the lumen, for rapid deflation of a balloon. Various embodiments hasten the deflation process and simplify the manipulation required by the surgeon.

Endoscopic tools for the removal of balloon-like intragastric devices

A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive implants do not autonomously change shape, but instead react within the stomach to induce satiety. The implants may take up volume within the stomach, thus reducing the digestive capacity. Additionally, the implants may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Also, a number of implants slow gastric emptying by blocking or otherwise impeding flow through the pyloric sphincter. Other implants delay digestion by providing a duodenal sleeve. A number of implants combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the implants within a delivery tube and transorally advancing the implants through the esophagus to be deployed within the stomach. Removal of the implants occurs in the reverse.

Stomach-spanning gastric implants

An intragastric obesity treatment implant promotes a feeling of satiety in the patient by contacting the insides of the stomach wall, reducing the space in the stomach, or otherwise reducing the amount of food consumed. One intragastric obesity treatment implant two inflatable balloons coupled via a flow restrictor through which fluid may flow in response to peristaltic motions of a patient's stomach. Additionally, one implant comprises a pumping chamber coupled to a reservoir, where the pumping chamber moves stomach fluids into the reservoir in response to peristaltic motions of the patient's stomach.

Intragastric implants with multiple fluid chambers

In one embodiment, the handheld injection device includes a first housing having a first axis and a second housing having a second axis. In one embodiment, the second housing is configured to support a needle. In one embodiment, the first axis and a second axis form an adjustable angle between about 180 degrees and about 90 degrees.

Injection device having an angled tip portion

Variable size intragastric implant devices

A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices may not autonomously change shape, but instead react within the stomach to induce satiety. The devices may provide slowed entry into the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Some devices combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse. The implants are formed of materials that permit the implant to be compressed into a substantially linear transoral delivery configuration and that will resist degradation over a period of at least six months within the stomach.

The medical systems, apparatuses and uses thereof for treating obesity and/or obesity-related diseases are provided which relate to devices designed to stimulate an internal surface of the stomach such as the cardia. Features of the obesity treatment devices include insertion of said devices transorally and without invasive surgery, without associated patient risks of invasive surgery, and without substantial patient discomfort. The devices include flotation portions and cardia-stimulating portions, so that as the level of stomach contents rise, the devices will contact and stimulate the nerves in the cardia region of the stomach to induce satiety. The devices may have non-inflatable balls, be made of skinned foam, have ballast members such as a weighted ball or quantity of saline for orientation, and various combinations thereof.

Growing community of inventors

Santa Clarita, CA, United States of America

Mitchell H Babkes